Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
NCT04735367
·
clinicaltrials.gov ↗
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
palbociclib plus letrozole
Sponsor
Pfizer